Zimmer Partners’s Inozyme Pharma INZY Stock Holding History

Zimmer Partners’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,000	Closed	-$263K	–	144
2020 Q3	$263K	Buy	+10,000	New	+$248K	﹤0.01%	118

Other funds holding INZY

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Zimmer Partners's INZY Position: Q4 2020 in Review

Zimmer Partners sold out of Inozyme Pharma (INZY) in Q4 2020, closing a stake of 10,000 shares — an estimated $263K sold.

Zimmer Partners first reported a position in INZY in Q3 2020 and held it in 1 quarter. The position peaked at $263K in Q3 2020. 54 funds tracked by Wall St. Rank hold INZY as of Q4 2020.

Zimmer Partners reported no remaining Inozyme Pharma position as of Q4 2020 after selling out during the quarter.
Zimmer Partners sold 10,000 Inozyme Pharma shares in Q4 2020, an estimated $263K.
Zimmer Partners first reported a position in Inozyme Pharma in Q3 2020 and held it in 1 quarter.
Zimmer Partners's Inozyme Pharma position peaked at $263K in Q3 2020.
54 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2020.

Based on Zimmer Partners's 13F filing for Q4 2020, filed 16 Feb 2021.